Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma
Trachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM in C. trachomatis has not been reported, there have been conc...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Journal of Tropical Medicine |
Online Access: | http://dx.doi.org/10.1155/2015/917370 |
id |
doaj-f19907bd56b34938900a7f072cd972cc |
---|---|
record_format |
Article |
spelling |
doaj-f19907bd56b34938900a7f072cd972cc2020-11-24T23:54:04ZengHindawi LimitedJournal of Tropical Medicine1687-96861687-96942015-01-01201510.1155/2015/917370917370Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for TrachomaDerek K-H. Ho0Christian Sawicki1Nicholas Grassly2Department of Ophthalmology, William Harvey Hospital, Kennington Road, Willesborough, Ashford, Kent TN24 0LZ, UKDepartment of Anesthesia, University of Toronto, 123 Edward Street, Toronto, ON, M5G 1E2, CanadaSchool of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UKTrachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM in C. trachomatis has not been reported, there have been concerns about resistance in other organisms when AZM is administered in community settings. We identified studies that measured pneumococcal prevalence and resistance to AZM following mass AZM provision reported up to 2013 in Medline and Web of Science databases. Potential sources of bias were assessed using the Cochrane Risk of Bias Tool. A total of 45 records were screened, of which 8 met the inclusion criteria. We identified two distinct trends of resistance prevalence, which are dependent on frequency of AZM provision and baseline prevalence of resistance. We also demonstrated strong correlation between the prevalence of resistance at baseline and at 2-3 months (r=0.759). Although resistance to AZM in C. trachomatis has not been reported, resistance to this commonly used macrolide antibiotic in other diseases could compromise treatment. This should be considered when planning long-term trachoma control strategies.http://dx.doi.org/10.1155/2015/917370 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Derek K-H. Ho Christian Sawicki Nicholas Grassly |
spellingShingle |
Derek K-H. Ho Christian Sawicki Nicholas Grassly Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma Journal of Tropical Medicine |
author_facet |
Derek K-H. Ho Christian Sawicki Nicholas Grassly |
author_sort |
Derek K-H. Ho |
title |
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma |
title_short |
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma |
title_full |
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma |
title_fullStr |
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma |
title_full_unstemmed |
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma |
title_sort |
antibiotic resistance in streptococcus pneumoniae after azithromycin distribution for trachoma |
publisher |
Hindawi Limited |
series |
Journal of Tropical Medicine |
issn |
1687-9686 1687-9694 |
publishDate |
2015-01-01 |
description |
Trachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin (AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM in C. trachomatis has not been reported, there have been concerns about resistance in other organisms when AZM is administered in community settings. We identified studies that measured pneumococcal prevalence and resistance to AZM following mass AZM provision reported up to 2013 in Medline and Web of Science databases. Potential sources of bias were assessed using the Cochrane Risk of Bias Tool. A total of 45 records were screened, of which 8 met the inclusion criteria. We identified two distinct trends of resistance prevalence, which are dependent on frequency of AZM provision and baseline prevalence of resistance. We also demonstrated strong correlation between the prevalence of resistance at baseline and at 2-3 months (r=0.759). Although resistance to AZM in C. trachomatis has not been reported, resistance to this commonly used macrolide antibiotic in other diseases could compromise treatment. This should be considered when planning long-term trachoma control strategies. |
url |
http://dx.doi.org/10.1155/2015/917370 |
work_keys_str_mv |
AT derekkhho antibioticresistanceinstreptococcuspneumoniaeafterazithromycindistributionfortrachoma AT christiansawicki antibioticresistanceinstreptococcuspneumoniaeafterazithromycindistributionfortrachoma AT nicholasgrassly antibioticresistanceinstreptococcuspneumoniaeafterazithromycindistributionfortrachoma |
_version_ |
1725467423481528320 |